Clinical Trial Update: Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating mitoxantrone hydrochloride liposome injection for Neuromyelitis Optica Spectrum Disorder has completed, reporting its effica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Mitoxantrone Hydrochloride Liposome Injection (mitoxantrone hydrochloride liposome)

Snippet

Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Conditions: Neuromyelitis Optica Spectrum Disorder | Phase 2 | Status: COMPLETED